Pulmatrix Inc. (2PU)

Overview

Pulmatrix, Inc. is a pioneering clinical stage biotechnology firm rooted in the United States, committed to the discovery and development of innovative inhaled therapies aimed at preventing and treating a wide range of respiratory conditions and other diseases that currently have unmet medical needs. Central to their strategy is the utilization of their proprietary iSPERSE (inhaled small particles easily respirable and emitted) technology. This technology stands out by enabling the effective delivery of both small and large molecule drugs directly to the lungs through inhalation, catering to local or systemic medical applications. Founded in the year 2003 and with its headquarters in Lexington, Massachusetts, Pulmatrix is positioned at the forefront of addressing critical respiratory conditions with groundbreaking therapeutic solutions.

Products and Services

• PUR1800: This innovative therapeutic candidate embodies a narrow spectrum kinase inhibitor and has successfully completed Phase 1b clinical trials. It is specifically formulated for patients suffering from stable moderate to severe chronic obstructive pulmonary disease (COPD), offering a promising new avenue for managing this debilitating respiratory condition.

• PUR1900: Aimed at addressing the needs of patients with allergic bronchopulmonary aspergillosis (ABPA), particularly those with concurrent asthma and cystic fibrosis, PUR1900 is a testament to Pulmatrix's commitment to tackling complex respiratory diseases. Through its development, the company seeks to provide a significant improvement in the treatment options available for managing the underlying fungal infections that exacerbate these conditions.

• PUR3100: As part of Pulmatrix's diverse product portfolio, PUR3100 is an iSPERSE-formulated version of dihydroergotamine, developed for the acute treatment of migraine. By leveraging their inhalation technology, Pulmatrix aims to offer a rapid, effective solution for migraine sufferers, underscoring the versatility of the iSPERSE technology in addressing a variety of health concerns beyond respiratory diseases.

In their quest to bring these innovative treatments to market, Pulmatrix has established strategic partnerships, including a license agreement with RespiVert Ltd., granting them access to a comprehensive portfolio of kinase inhibitor drug candidates. Additionally, a development and commercialization agreement with Cipla Technologies LLC for PUR1900 marks a significant step towards achieving broader distribution and accessibility for their therapies. With these alliances, Pulmatrix is well-equipped to navigate the complex path from research and development to commercial success, ultimately delivering on their promise to address unmet medical needs through groundbreaking inhaled therapies.